The research compound in Mounjaro®
Mounjaro® is a type 2 diabetes medicine from Eli Lilly and Company. Its active compound is Tirzepatide — which is what this catalogue supplies, as a research material.
This is not Mounjaro®, and NOVALYTE LABS has no affiliation with Eli Lilly and Company. We supply the compound Tirzepatide for laboratory research only — not for human consumption, diagnostic, therapeutic or veterinary use. Mounjaro® is a trademark of Eli Lilly and Company, referenced here only to identify the compound.
Mounjaro is the brand under which Eli Lilly markets tirzepatide for type 2 diabetes. The same molecule is marketed as Zepbound for weight management — one compound, two brands, two indications.
Tirzepatide itself is a dual agonist: a single 39-amino-acid peptide engineered to activate both the GIP and GLP-1 receptors, which is what distinguishes it from the single-receptor GLP-1 agonists that preceded it.
What this catalogue supplies is tirzepatide as a research material, with batch documentation. It is not Mounjaro, it is not a medicine, and it is not supplied for human use.
Tirzepatide in this catalogue
2.5mg × 4 pens
How Tirzepatide is supplied here
Everything below describes the research material in this catalogue, not the medicine. Tirzepatide is stocked in 4 presentations, so the figures below are for the base one.
| Compound | Tirzepatide |
|---|---|
| Presentation | 2.5mg × 4 pens |
| Dosage options | 2.5mg × 4 pens · 5mg × 4 pens · 10mg × 4 pens · 15mg × 4 pens |
| Research category | Metabolic Research |
| Batch COA | Certificate supplied with order |
| Availability | In stock |
| Intended use | Laboratory research only — not for human or veterinary use |
Common questions
What is the active compound in Mounjaro?
Tirzepatide. Mounjaro is a registered trademark of Eli Lilly and Company, approved for type 2 diabetes.
Is this Mounjaro?
No. NOVALYTE LABS supplies Tirzepatide as a research material with batch documentation. It is not Mounjaro, it is not a medicine, it is not supplied for human use, and there is no affiliation with Eli Lilly and Company.
Why is Tirzepatide sold under more than one brand?
Because a brand is tied to an approved indication rather than to the molecule. Tirzepatide is marketed as Mounjaro and also as Zepbound — same compound, different approvals.
Other brands using Tirzepatide
The same compound is marketed under more than one brand, usually because each brand carries a different approved indication.